Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation
- 4 March 2013
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (10) , 2200-2204
Abstract
Progression or relapse occurs in the vast majority of patients with multiple myeloma (MM) who undergo up-front autologous hematopoietic cell transplantation (AHCT1), which remains a cornerstone of treatment in the era of novel agents. Limited data are available regarding the value of salvage therapy with a second AHCT (AHCT2) in patients who relapse/progress after AHCT1. We analyzed the outcome of 83 patients who underwent salvage AHCT2 between 1994 and 2011. Most patients (77%) had received treatment with novel agents between AHCT1 and AHCT2, and 28% of patients were from ethnic minority groups. Median overall survival (OS) from AHCT2 was 31.5 months (95% confidence interval [CI]: 22–41), and median progression-free survival (PFS) was 15.5 months (95% CI: 11–20). In multivariate analysis, only disease status (≥ PR) at AHCT2 was associated with better OS. The 3-year OS rates for patients receiving AHCT2 in > PR and PR were 85.9% (95% CI: 61–96) and 51.3% (95% CI: 34–68), respectively. Disease status at AHCT2 and time to progression/relapse after AHCT1 were associated with PFS in multivariate analysis. In summary, salvage AHCT2 is an effective treatment option in patients with chemosensitive relapse/progression and prolonged remission after a prior autograft.Keywords
This publication has 21 references indexed in Scilit:
- Durable remission with salvage second autotransplants in patients with multiple myelomaCancer, 2011
- Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare systemBritish Journal of Haematology, 2011
- Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation RegistryTransplantation and Cellular Therapy, 2011
- Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantationEuropean Journal of Haematology, 2011
- Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel TherapiesJournal of Clinical Oncology, 2011
- Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple MyelomaTransplantation and Cellular Therapy, 2010
- Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaBone Marrow Transplantation, 2008
- The impact of race on outcomes of autologous transplantation in patients with multiple myelomaAmerican Journal of Hematology, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myelomaBone Marrow Transplantation, 2006